Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP
Author Information
Author(s): Yuan Yuan, Liao Yu-Min, Hsueh Chung-Tsen, Mirshahidi Hamid R
Primary Institution: Loma Linda University Medical Center
Conclusion
The review summarizes the preclinical and clinical development of MDM2, ALK, and PARP inhibitors, highlighting their potential in targeted cancer therapies.
Supporting Evidence
- MDM2 inhibitors can restore p53 activity in cancers with wild-type p53.
- ALK inhibitors have shown promising activity in non-small cell lung cancer with EML4-ALK fusion.
- PARP inhibitors improve clinical outcomes in patients with triple-negative breast cancer.
Takeaway
This study looks at new medicines that can help fight cancer by targeting specific parts of cancer cells, making treatments more effective and less harmful.
Methodology
The review includes analysis of preclinical data and clinical studies on MDM2, ALK, and PARP inhibitors.
Potential Biases
Potential bias in the selection of studies and data interpretation may exist.
Limitations
The review does not provide long-term safety data or the effectiveness of these inhibitors in diverse patient populations.
Participant Demographics
The study involved patients with advanced solid tumors, including various cancer types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website